Optimisation of management in clinical oncology


Ontology type: schema:MonetaryGrant     


Grant Info

YEARS

2009-2015

FUNDING AMOUNT

N/A

ABSTRACT

Radiotherapy is used widely in the curative treatment of localised cancers, a goal which becomes increasingly important as advances in chemotherapy improve the control of micro-metastases. The new techniques of intensity modulated radiotherapy coupled with functional imaging permit radiation dose boosting to resistant sub-targets within a tumour, such as areas of hypoxia or rapid proliferation. One limitation of these approaches is target mobility due to respiratory, cardiac, bowel and bladder movement. Methods to identify and treat sub-targets and to measure and account for these movements - image guided radiotherapy (IGRT) - need to be developed and applied in clinical practice. Precise radiation targeting also provides the opportunity to intensify treatment with concomitant relevant biologically-targeted agents. The proposals in this application continue the close collaboration between academic radiotherapy and research physics, and exploit our links with other research groups on-site, including Cancer Research UK Centres (Molecular Biology, Cancer Therapeutics and Imaging). They extend from conceptual and laboratory developments to translational pre-clinical studies and clinical trials and include analyses of physics and outcome data as well as tissue from these trials. The overarching aim is to increase cancer control and cure whilst moderating treatment related side effects. Last updated 21/07/2010 More... »

Related SciGraph Publications

  • 2017-09-05. Pre-clinical imaging of transgenic mouse models of neuroblastoma using a dedicated 3-element solenoid coil on a clinical 3T platform in BRITISH JOURNAL OF CANCER
  • 2017-09-05. Predicting response to radical (chemo)radiotherapy with circulating HPV DNA in locally advanced head and neck squamous carcinoma in BRITISH JOURNAL OF CANCER
  • 2017-08. Symptom clusters for revising scale membership in the analysis of prostate cancer patient reported outcome measures: a secondary data analysis of the Medical Research Council RT01 trial (ISCRTN47772397) in QUALITY OF LIFE RESEARCH
  • 2017-04. Phase I/II trials of 186Re-HEDP in metastatic castration-resistant prostate cancer: post-hoc analysis of the impact of administered activity and dosimetry on survival in EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
  • 2017-04. The Role of Hypofractionated Radiotherapy in Prostate Cancer in CURRENT ONCOLOGY REPORTS
  • 2017-01. Blood transfusion during radical chemo-radiotherapy does not reduce tumour hypoxia in squamous cell cancer of the head and neck in BRITISH JOURNAL OF CANCER
  • 2016-12. Classification of fibroglandular tissue distribution in the breast based on radiotherapy planning CT in BMC MEDICAL IMAGING
  • 2016-09. Delayed DNA double-strand break repair following platin-based chemotherapy predicts treatment response in head and neck squamous cell carcinoma in BRITISH JOURNAL OF CANCER
  • 2016-08. Evaluation of radiotherapy techniques for radical treatment of lateralised oropharyngeal cancers in STRAHLENTHERAPIE UND ONKOLOGIE
  • 2016-05. Common genetic variation associated with increased susceptibility to prostate cancer does not increase risk of radiotherapy toxicity in BRITISH JOURNAL OF CANCER
  • 2015-12. Comparison of CT number calibration techniques for CBCT-based dose calculation in STRAHLENTHERAPIE UND ONKOLOGIE
  • 2015-12. Prospective, longitudinal, multi-modal functional imaging for radical chemo-IMRT treatment of locally advanced head and neck cancer: the INSIGHT study in RADIATION ONCOLOGY
  • 2015-07. The tumour microenvironment after radiotherapy: mechanisms of resistance and recurrence in NATURE REVIEWS CANCER
  • 2015-05. Multivariate modelling of prostate cancer combining magnetic resonance derived T2, diffusion, dynamic contrast-enhanced and spectroscopic parameters in EUROPEAN RADIOLOGY
  • 2015-05. Selective organ preservation with neo-adjuvant chemotherapy for the treatment of muscle invasive transitional cell carcinoma of the bladder in BRITISH JOURNAL OF CANCER
  • 2014-12. Tumour responses following a steroid switch from prednisone to dexamethasone in castration-resistant prostate cancer patients progressing on abiraterone in BRITISH JOURNAL OF CANCER
  • 2014-12. Cytokine levels as biomarkers of radiation fibrosis in patients treated with breast radiotherapy in RADIATION ONCOLOGY
  • 2014-08. A three-stage genome-wide association study identifies a susceptibility locus for late radiotherapy toxicity at 2q24.1 in NATURE GENETICS
  • 2014-08. Haste makes waste: Are the data regarding TARGIT-A IORT ready for prime time? in BREAST CANCER RESEARCH AND TREATMENT
  • 2014-05. DNA double-strand break repair and induction of apoptosis in ex vivo irradiated blood lymphocytes in relation to late normal tissue reactions following breast radiotherapy in RADIATION AND ENVIRONMENTAL BIOPHYSICS
  • 2014-01. Reply: ‘Comment on Anti-tumour activity of abiraterone and diethylstilboestrol when administered sequentially to men with castration-resistant prostate cancer’ in BRITISH JOURNAL OF CANCER
  • 2014-01. Second cancer risk and mortality in men treated with radiotherapy for stage I seminoma in BRITISH JOURNAL OF CANCER
  • 2013-12. Advances in bladder cancer imaging in BMC MEDICINE
  • 2013-09. Antitumour activity of abiraterone and diethylstilboestrol when administered sequentially to men with castration-resistant prostate cancer in BRITISH JOURNAL OF CANCER
  • 2013-08. Randomised pilot study of dose escalation using conformal radiotherapy in prostate cancer: long-term follow-up in BRITISH JOURNAL OF CANCER
  • 2013-05. Synergistic cytotoxicity of oncolytic reovirus in combination with cisplatin–paclitaxel doublet chemotherapy in GENE THERAPY
  • 2013-04. Identification of 23 new prostate cancer susceptibility loci using the iCOGS custom genotyping array in NATURE GENETICS
  • 2012-12. Analysis of Xq27-28 linkage in the international consortium for prostate cancer genetics (ICPCG) families in BMC MEDICAL GENETICS
  • 2012-11. DNA fusion-gene vaccination in patients with prostate cancer induces high-frequency CD8+ T-cell responses and increases PSA doubling time in CANCER IMMUNOLOGY, IMMUNOTHERAPY
  • 2012-10. Combining advanced radiotherapy technologies to maximize safety and tumor control probability in stage III non-small cell lung cancer in STRAHLENTHERAPIE UND ONKOLOGIE
  • 2012-04. An exploratory study of the influence of clinico-demographic variables on swallowing and swallowing-related quality of life in a cohort of oral and oropharyngeal cancer patients treated with primary surgery in EUROPEAN ARCHIVES OF OTO-RHINO-LARYNGOLOGY
  • 2012-02. Evaluation of factors affecting post-treatment quality of life in oral and oropharyngeal cancer patients primarily treated with curative surgery: an exploratory study in EUROPEAN ARCHIVES OF OTO-RHINO-LARYNGOLOGY
  • 2011-12. 18F-fluoride PET: changes in uptake as a method to assess response in bone metastases from castrate-resistant prostate cancer patients treated with 223Ra-chloride (Alpharadin) in EJNMMI RESEARCH
  • 2011-12. Gene expression profiling of human dermal fibroblasts exposed to bleomycin sulphate does not differentiate between radiation sensitive and control patients in RADIATION ONCOLOGY
  • 2011-12. Key issues in recruitment to randomised controlled trials with very different interventions: a qualitative investigation of recruitment to the SPARE trial (CRUK/07/011) in TRIALS
  • 2011-10. Multicentric breast cancer: clonality and prognostic studies in BREAST CANCER RESEARCH AND TREATMENT
  • 2011-08. Seven prostate cancer susceptibility loci identified by a multi-stage genome-wide association study in NATURE GENETICS
  • 2011-08. Effects of lapatinib monotherapy: results of a randomised phase II study in therapy-naive patients with locally advanced squamous cell carcinoma of the head and neck in BRITISH JOURNAL OF CANCER
  • 2011-08. Guidelines for preclinical and early phase clinical assessment of novel radiosensitisers in BRITISH JOURNAL OF CANCER
  • 2011-04. A Bayesian hierarchical model for DCE-MRI to evaluate treatment response in a phase II study in advanced squamous cell carcinoma of the head and neck in MAGNETIC RESONANCE MATERIALS IN PHYSICS, BIOLOGY AND MEDICINE
  • 2011-01. The diagnostic utility of the flare phenomenon on bone scintigraphy in staging prostate cancer in EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
  • 2011-01. Hand pattern indicates prostate cancer risk in BRITISH JOURNAL OF CANCER
  • 2010-09. Prostate cancer in BRCA2 germline mutation carriers is associated with poorer prognosis in BRITISH JOURNAL OF CANCER
  • 2010-04. Serum micronutrient and antioxidant levels at baseline and the natural history of men with localised prostate cancer on active surveillance in TUMOR BIOLOGY
  • 2009-12. Issues in applying multi-arm multi-stage methodology to a clinical trial in prostate cancer: the MRC STAMPEDE trial in TRIALS
  • 2009-10. Identification of seven new prostate cancer susceptibility loci through a genome-wide association study in NATURE GENETICS
  • 2009-10. Multiple loci on 8q24 associated with prostate cancer susceptibility in NATURE GENETICS
  • 2009-07. Optimization and assessment of quantitative 124I imaging on a Philips Gemini dual GS PET/CT system in EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
  • 2009-06. Biopsy tissue microarray study of Ki-67 expression in untreated, localized prostate cancer managed by active surveillance in PROSTATE CANCER AND PROSTATIC DISEASES
  • JSON-LD is the canonical representation for SciGraph data.

    TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

    [
      {
        "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
        "about": [
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/2211", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "type": "DefinedTerm"
          }
        ], 
        "description": "Radiotherapy is used widely in the curative treatment of localised cancers, a goal which becomes increasingly important as advances in chemotherapy improve the control of micro-metastases. The new techniques of intensity modulated radiotherapy coupled with functional imaging permit radiation dose boosting to resistant sub-targets within a tumour, such as areas of hypoxia or rapid proliferation. One limitation of these approaches is target mobility due to respiratory, cardiac, bowel and bladder movement. Methods to identify and treat sub-targets and to measure and account for these movements - image guided radiotherapy (IGRT) - need to be developed and applied in clinical practice. Precise radiation targeting also provides the opportunity to intensify treatment with concomitant relevant biologically-targeted agents. The proposals in this application continue the close collaboration between academic radiotherapy and research physics, and exploit our links with other research groups on-site, including Cancer Research UK Centres (Molecular Biology, Cancer Therapeutics and Imaging). They extend from conceptual and laboratory developments to translational pre-clinical studies and clinical trials and include analyses of physics and outcome data as well as tissue from these trials. The overarching aim is to increase cancer control and cure whilst moderating treatment related side effects. Last updated 21/07/2010", 
        "endDate": "2015-09-30T00:00:00Z", 
        "funder": {
          "id": "https://www.grid.ac/institutes/grid.11485.39", 
          "type": "Organization"
        }, 
        "id": "sg:grant.5137829", 
        "identifier": [
          {
            "name": "dimensions_id", 
            "type": "PropertyValue", 
            "value": [
              "5137829"
            ]
          }, 
          {
            "name": "pmc_id", 
            "type": "PropertyValue", 
            "value": [
              "CRUK-A10588"
            ]
          }
        ], 
        "inLanguage": [
          "en"
        ], 
        "keywords": [
          "trials", 
          "treatment", 
          "opportunity", 
          "control", 
          "IGRT", 
          "advances", 
          "target mobility", 
          "close collaboration", 
          "research physics", 
          "intensity", 
          "laboratory development", 
          "tissue", 
          "bowel", 
          "Cancer Therapeutics", 
          "Cancer Research UK Centres", 
          "approach", 
          "hypoxia", 
          "other research groups", 
          "area", 
          "overarching aim", 
          "imaging", 
          "analysis", 
          "clinical practice", 
          "clinical trials", 
          "METHODS", 
          "Precise radiation targeting", 
          "rapid proliferation", 
          "curative treatment", 
          "functional imaging permit radiation dose", 
          "side effects", 
          "application", 
          "tumor", 
          "physics", 
          "sites", 
          "proposal", 
          "cure", 
          "Clinical Oncology", 
          "link", 
          "micro-metastases", 
          "agents", 
          "translational pre-clinical studies", 
          "cancer control", 
          "limitations", 
          "outcome data", 
          "bladder movement", 
          "radiotherapy", 
          "cancer", 
          "sub-targets", 
          "new technique", 
          "movement-image", 
          "resistant sub-targets", 
          "chemotherapy", 
          "management", 
          "goal", 
          "optimization", 
          "molecular biology"
        ], 
        "name": "Optimisation of management in clinical oncology", 
        "recipient": [
          {
            "id": "https://www.grid.ac/institutes/grid.18886.3f", 
            "type": "Organization"
          }, 
          {
            "affiliation": {
              "id": "https://www.grid.ac/institutes/grid.18886.3f", 
              "name": "Institute Of Cancer Research", 
              "type": "Organization"
            }, 
            "familyName": "Horwich", 
            "givenName": "Alan", 
            "id": "sg:person.01140223356.38", 
            "type": "Person"
          }, 
          {
            "member": "sg:person.01140223356.38", 
            "roleName": "PI", 
            "type": "Role"
          }
        ], 
        "sameAs": [
          "https://app.dimensions.ai/details/grant/grant.5137829"
        ], 
        "sdDataset": "grants", 
        "sdDatePublished": "2021-01-19T03:52", 
        "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
        "sdPublisher": {
          "name": "Springer Nature - SN SciGraph project", 
          "type": "Organization"
        }, 
        "sdSource": "s3://com.uberresearch.data.processor/core_data/20181219_192338/projects/base/pmc_projects.xml.gz", 
        "startDate": "2009-10-01T00:00:00Z", 
        "type": "MonetaryGrant"
      }
    ]
     

    Download the RDF metadata as:  json-ld nt turtle xml License info

    HOW TO GET THIS DATA PROGRAMMATICALLY:

    JSON-LD is a popular format for linked data which is fully compatible with JSON.

    curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/grant.5137829'

    N-Triples is a line-based linked data format ideal for batch operations.

    curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/grant.5137829'

    Turtle is a human-readable linked data format.

    curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/grant.5137829'

    RDF/XML is a standard XML format for linked data.

    curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/grant.5137829'


     

    This table displays all metadata directly associated to this object as RDF triples.

    95 TRIPLES      17 PREDICATES      76 URIs      68 LITERALS      4 BLANK NODES

    Subject Predicate Object
    1 sg:grant.5137829 schema:about anzsrc-for:2211
    2 schema:description Radiotherapy is used widely in the curative treatment of localised cancers, a goal which becomes increasingly important as advances in chemotherapy improve the control of micro-metastases. The new techniques of intensity modulated radiotherapy coupled with functional imaging permit radiation dose boosting to resistant sub-targets within a tumour, such as areas of hypoxia or rapid proliferation. One limitation of these approaches is target mobility due to respiratory, cardiac, bowel and bladder movement. Methods to identify and treat sub-targets and to measure and account for these movements - image guided radiotherapy (IGRT) - need to be developed and applied in clinical practice. Precise radiation targeting also provides the opportunity to intensify treatment with concomitant relevant biologically-targeted agents. The proposals in this application continue the close collaboration between academic radiotherapy and research physics, and exploit our links with other research groups on-site, including Cancer Research UK Centres (Molecular Biology, Cancer Therapeutics and Imaging). They extend from conceptual and laboratory developments to translational pre-clinical studies and clinical trials and include analyses of physics and outcome data as well as tissue from these trials. The overarching aim is to increase cancer control and cure whilst moderating treatment related side effects. Last updated 21/07/2010
    3 schema:endDate 2015-09-30T00:00:00Z
    4 schema:funder https://www.grid.ac/institutes/grid.11485.39
    5 schema:identifier N95acd7f6c70c4dc196e4b9e70740f6b4
    6 Nfcbd4cf33648430bbdb3e52c588ce9fc
    7 schema:inLanguage en
    8 schema:keywords Cancer Research UK Centres
    9 Cancer Therapeutics
    10 Clinical Oncology
    11 IGRT
    12 METHODS
    13 Precise radiation targeting
    14 advances
    15 agents
    16 analysis
    17 application
    18 approach
    19 area
    20 bladder movement
    21 bowel
    22 cancer
    23 cancer control
    24 chemotherapy
    25 clinical practice
    26 clinical trials
    27 close collaboration
    28 control
    29 curative treatment
    30 cure
    31 functional imaging permit radiation dose
    32 goal
    33 hypoxia
    34 imaging
    35 intensity
    36 laboratory development
    37 limitations
    38 link
    39 management
    40 micro-metastases
    41 molecular biology
    42 movement-image
    43 new technique
    44 opportunity
    45 optimization
    46 other research groups
    47 outcome data
    48 overarching aim
    49 physics
    50 proposal
    51 radiotherapy
    52 rapid proliferation
    53 research physics
    54 resistant sub-targets
    55 side effects
    56 sites
    57 sub-targets
    58 target mobility
    59 tissue
    60 translational pre-clinical studies
    61 treatment
    62 trials
    63 tumor
    64 schema:name Optimisation of management in clinical oncology
    65 schema:recipient N68eed91dbeb44637b3d9a8f1df69e66b
    66 sg:person.01140223356.38
    67 https://www.grid.ac/institutes/grid.18886.3f
    68 schema:sameAs https://app.dimensions.ai/details/grant/grant.5137829
    69 schema:sdDatePublished 2021-01-19T03:52
    70 schema:sdLicense https://scigraph.springernature.com/explorer/license/
    71 schema:sdPublisher N7f8e2a2dd1d64c3bb8af9fc27212e041
    72 schema:startDate 2009-10-01T00:00:00Z
    73 sgo:license sg:explorer/license/
    74 sgo:sdDataset grants
    75 rdf:type schema:MonetaryGrant
    76 N68eed91dbeb44637b3d9a8f1df69e66b schema:member sg:person.01140223356.38
    77 schema:roleName PI
    78 rdf:type schema:Role
    79 N7f8e2a2dd1d64c3bb8af9fc27212e041 schema:name Springer Nature - SN SciGraph project
    80 rdf:type schema:Organization
    81 N95acd7f6c70c4dc196e4b9e70740f6b4 schema:name pmc_id
    82 schema:value CRUK-A10588
    83 rdf:type schema:PropertyValue
    84 Nfcbd4cf33648430bbdb3e52c588ce9fc schema:name dimensions_id
    85 schema:value 5137829
    86 rdf:type schema:PropertyValue
    87 anzsrc-for:2211 schema:inDefinedTermSet anzsrc-for:
    88 rdf:type schema:DefinedTerm
    89 sg:person.01140223356.38 schema:affiliation https://www.grid.ac/institutes/grid.18886.3f
    90 schema:familyName Horwich
    91 schema:givenName Alan
    92 rdf:type schema:Person
    93 https://www.grid.ac/institutes/grid.11485.39 schema:Organization
    94 https://www.grid.ac/institutes/grid.18886.3f schema:name Institute Of Cancer Research
    95 rdf:type schema:Organization
     




    Preview window. Press ESC to close (or click here)


    ...